Sucampo Pharmaceuticals, Inc. Uncategorized Contracts & Agreements

39 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
AMENDED AND RESTATED EXECUTIVE EMPLOYMENTAGREEMENT
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2016
AMENDED AND RESTATED EXECUTIVE EMPLOYMENTAGREEMENT
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2016
AMENDED AND RESTATED EXECUTIVE EMPLOYMENTAGREEMENT
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2016
AMENDED AND RESTATED EXECUTIVE EMPLOYMENTAGREEMENT
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2016
AMENDED AND RESTATED EXECUTIVEEMPLOYMENT AGREEMENT
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2016
OPTION AND COLLABORATIONAGREEMENT
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
NY
2016
STRATEGIC ALLIANCE AGREEMENT dated as of August 26, 2015 among Sucampo Pharmaceuticals, Inc., Sucampo Pharma, LLC. and R-Tech Ueno, Ltd.
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
DE
2015
AMENDMENT NO. 1 TO AGREEMENT
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2014
Confidential1 Ryuji Ueno
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2014
EMPLOYMENTAGREEMENT
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2012
Agreement on Bank Overdrafts (Through an Account Used Exclusively for the Purpose of Bank Overdrafts) (Customer Copy)
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2011
Special Agreement
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2011
NON-COMPETITIONAGREEMENT
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2010
Condensed Consolidated Financial Statements (Unaudited)
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2009
Page 1 of 41
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
NY
2009
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of The...
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
WA
2009
ADDENDUM TO AMENDED AND RESTATED PATENT ACCESS AGREEMENT: REDUCTION OF ROYALTIES WITH RESPECT TO SPL TERRITORY
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2009
AMENDED AND RESTATED
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
DE
2008
INDEPENDENT CONTRACTOR AGREEMENT
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2008
SUCAMPO PHARMACEUTICALS, INC.
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
DE
2007
SPI-8811 (cobiprostone) for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, disorders...
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2007
SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, disorders associated with...
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2007
SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, disorders associated with...
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2007
SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and...
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2007
SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and...
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2007
SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and...
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2007
SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and...
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
NY
2007
SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and...
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
NY
2007
SPI-8811 for the treatment of ulcers induced by non-steroidal anti-inflammatory drugs, or NSAIDs, portal hypertension, non-alcoholic fatty liver disease, cystic fibrosis and...
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2007
Confidentialmaterials omitted and filed separately with the Securities andExchange Commission. Asterisks denote omissions.
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2006
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2006
Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
MD
2006
Amended and Restated
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
NY
2006
ConfidentialMaterials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
NY
2006
ConfidentialMaterials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
NY
2006
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
NY
2006
ConfidentialMaterials omitted and filed separately with the Securities and ExchangeCommission. Asterisks denote omissions.
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
NY
2006
Confidential Materials omitted and filed separately with the
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
NY
2006
4733 BETHESDA AVENUE
Sucampo Pharmaceuticals, Inc.
Pharmaceuticals
2006